Tag: Victoza

While Victoza is a daily injectable medication primarily approved for managing type 2 diabetes, its active ingredient, liraglutide, has also demonstrated weight loss effects in clinical studies. This has led to its "off-label" use for weight management, but it's important to understand the distinctions between Victoza and the higher-dose version, Saxenda, which is FDA-approved for weight loss.

In October 2024, manufacturer Novo Nordisk confirmed the discontinuation of its Victoza (liraglutide) pens in the UK, citing a business decision to consolidate its portfolio. Despite persistent confusion and rumors, Victoza was not taken off the market due to a safety recall but rather phased out in certain regions in favor of newer, more effective medications.